Pembrolizumab, USFDA
Enfortumab vedotin-ejfv ine pembrolizumab inotenderwa neUSFDA kune yemuno advanced kana metastatic urothelial carcinoma.
Kukadzi 2024: Chikafu neDrug Administration yakamhanyisa nzira yekubvumidzwa kwemishonga miviri, enfortumab vedotin-ejfv (Padcev, Astellas Pharma) uye pembrolizumab (Keytruda, Merck). Mishonga iyi inoitirwa kurapa vanhu vemuno..
BMS, Bristol Myers squibb, immunotherapy, metastatic melanoma, nivolumab uye relatlimab, nivolumab uye relatlimab-rmbw, Opdualag, USFDA
Chekutanga LAG-3-Kuvharira antibody musanganiswa, Opdualag™ (nivolumab uye relatlimab-rmbw), inotenderwa neFDA kune varwere vane unresectable kana metastatic melanoma.
Kubvumbi 2022: Iyo US Chikafu neDrug Administration (FDA) yakabvumidza Opdualag (nivolumab uye relatlimab-rmbw), mutsva, wekutanga-mu-kirasi yakatarwa-dose musanganiswa we nivolumab uye relatlimab inopihwa seimwe intravenous infusion, f.
BMS, Breyanzi, MOTO - T Cell kurapwa, MOTO T-Cell, CART kurapa, USFDA
Breyanzi - Nyowani CAR T-Cell kurapwa kubva kuBMS
Chikunguru 2021: Breyanzi (Lisocabtagene maraleucel; liso-cel), inoveli CD19-inotungamirwa chimeric antigen receptor (CAR) T cell kurapwa yakagadziriswa naBristol Myers Squibb (BMS), yakabvumidzwa neUS Food and Drug Administration (US.
KEYTRUDA, Merck, NCT02362594, Pembrolizumab, GADZIRA, USFDA
Pembrolizumab inogamuchirwa neDFA yekurapa kwekuwedzera kwe melanoma
Musi waKukadzi 15, 2019, pembrolizumab (KEYTRUDA, Merck) yakabvumidzwa neFood and Drug Administration yekurapa adjuvant yevarwere vane melanoma nekubatanidzwa kwemalymph node (s) mushure mekuvhiyiwa kwakazara. Kubvumirwa..
Ablynx, ADAMTS13, CABLIVI, chivote-yhdp, FDA, immunosuppressive kurapa, USFDA
Caplacizumab-yhdp inogamuchirwa neDFA
Musi waFebruary 6, 2019, pamwe chete nekutsinhana kweplasma uye kurapwa kwekuzvidzivirira muviri, Kudya neDrug Administration yakabvumidza caplacizumab-yhdp (CABLIVI, Ablynx NV) yevakuru varwere vane thrombotic cystopeni.
CABOMETYX, Cabozantinib, Exelixis, FDA, HCC, hepatocellular carcinoma, Sorafenib, USFDA
Cabozantinib is FDA-inogamuchirwa yehepatocellular carcinoma
Musi waNdira 14, 2019, cabozantinib (CABOMETYX, Exelixis, Inc.) yakabvumidzwa neFood and Drug Administration kune varwere vane hepatocellular carcinoma (HCC) vakamborapwa sorafenib. The appr..
Acalabrutunib, Avelumab, CART kurapa, Dabrafanib, Kymriah, Dzazvino zvinodhaka, Midostaurin, Niraparib, Pembrolizumab, Tecartus, Tisagenlecleucel, Trametinib, USFDA
Dzazvino mishonga yekurapa kenza
Chikunguru 2021: Tarisa uone mishonga ichangoburwa mukurapa cancer. Gore rega rega, mushure mekuongorora miedzo uye zvimwe zvakakosha, USFDA inobvumidza mishonga, uye nekudaro varwere vegomarara vanogona kutenda kuti kurapwa kwave pedyo. ..